BIO US 2017
San Diego, June 2017
THERAVECTYS will join the BIO US 2017 to present its new portfolio strategy and meet with partner to identify out-licensing and co-development opportunities.
ASH Annual Meeting
Orlando, December 2015
The ASH Annual Meeting is the world's premier event in malignant & non-malignant hematology. The meeting provides an invaluable educational experience and an opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology.
IMVACS 10th annual meeting
Boston, September 2015
Wrapping up its tenth year, ImVacS played host to a record-breaking 320+ professionals working in immunotherapies and vaccines. The 2015 event brought with it a newly added plenary keynote, given by Dr. Polly Matzinger of the NIH, that touched upon everything from adjuvants to tregs while challenging assumptions and encouraging new ways of thinking.
Helsinki, September 2015
The ESGCT Annual Meeting provides an opportunity for scientists, clinicians and industry professionals to share new data, learn from peers, and discover global advances within the Gene and Cell Therapy field. With nearly 1000 participants from 40 countries, the ESGCT Annual Meeting is this year organised in collaboration with the Finnish Society of Gene Therapy.
Towards an HIV Cure 2015 / IAS 2015
Vancouver, July 2015
Towards an HIV Cure, an initiative of the International AIDS Society (IAS) provides leadership in facilitating more concerted efforts to accelerate global scientific research towards a cure for HIV and in advocating for increased investment in HIV cure research.
Hélène TOUSSAINT, Emeline SARRY, Ana BEJANARIU, Sophie AGAUGUE, Marie RODRIGUEZ, Emmanuelle SABBAH-PETROVER, Karima BELKHIRIA, Odile LAUNAY, Nathan CLUMECK, Michel MOUTSCHEN, Nathalie COLIN DE VERDIERE, Patrice MASSIP, Christian MICHELET, David REY, Christine JACOMET, Lionel PIROTH, Christian CHIDIAC, Frédéric LUCHT, Christine ROUZIOUX, Cécile BAUCHE.
New Orleans, May 2015
The 18th Annual Meeting will bring together 1,700 of the world’s top researchers, clinicians, fellows, and trainees for four days of education, presentations, networking, and social events.
Development of an inducible CAR-T Cell platform using Lentiviral vector
Sophie Agaugue, Emeline Sarry, Ana Bejanariu, Klervi Even-Desrumeaux, Abdel Zemmar, Cecile Bauche.
A comprehensive immunotherapeutic platform
Deborah Revaud, Sophie Agaugue, Emeline Sarry, Ana Bejanariu, Cecile Bauche.
A cGMP facility dedicated to the bioproduction of lentiviral-based therapeutic vaccines & other T-cell-based therapies
Abdel Zemmar, Guillaume Deplaine, Amel Hadri, Julien Deroyer, Cecile Bauche.
Successful development of a patented lyophilization process for lentiviral vector clinical batches
Nicolas Delacroix, Alice Pailleret, Julien Deroyer, Guillaume Deplaine, Cecile Bauche.
Boston, May 2015
The Essential Protein Engineering Summit is the premier event for antibody and protein science research and the biologics industry.
“Development of inducible CAR-T cells platform using lentiviral vectors” by Sophie AGAUGUE
Chimeric antigen receptors (CAR)–modified T cells have shown very promising clinical results in hematological malignancies but they still show toxicity due to a cytokine storm, even if it is manageable. Improving the safety while maintaining or even improving the anti-tumor efficacy of CAR-T cells is therefore a crucial therapeutic challenge. Based on our proprietary lentiviral vector technology, we are developing a new innovative CAR-T cells platform. This differentiating platform will overcome the main CAR-T cell limitations, namely the safety and the cost of the treatments. Indeed, the expression of the CAR at the surface of the T-cells is regulated by a proprietary reversible (switch) system, that can be turned ON or OFF on demand, especially in case of serious adverse events like cytokine storms.
In addition, most of the antigen-binding domain used to date are of murine origin and neutralizing antibodies against these murine domains can limit the efficacy of CAR. As an alternative, we are developing synthetic and humanized nanobodies to be used as binding domains since they are highly homologous to the human VH domain of antibodies and they display high antigen binding capacities.
Furthermore, based on this switch technology, THERAVECTYS is currently working to develop a one-step industrial process at the patient’s bedside.
The CAR technological platform developed by THERAVECTYS thus allows flexibility and reactivity in the CAR design, production and evaluation, leading to the generation of optimal inducible CAR-T cells which could become important players into the field of cellular immunotherapy.
“Development of novel anti-checkpoints strategies based on innovative lentiviral vectors” by Cécile BAUCHE
Tumors have evolved numerous mechanisms to escape immune surveillance, notably mechanisms linked to apoptosis, secretion of immunosuppressive molecules like IL-10 or TGFb, recruitment of immune suppressive cells such as regulatory T cells or myeloïd-derived suppressor cells, downregulation or loss of MHC molecules to alter antigen presentation, expression or induction of molecules inhibiting T cell activation like HLA-G, IDO, CTLA-4 or PD-1/PD-L1.
Among those mechanisms, the immune checkpoints PD-1/PD-L1 and CTLA-4 have been a focus of interest during the last years. CTLA-4 is expressed on T cells in the lymph nodes early during the immune response and acts as a physiological break to T cell activation to maintain a normal immune homeostasis. PD-1 is expressed in the periphery later once T cells have become activated to avoid auto-immune responses. These two mechanisms are used by tumors to dampen anti-tumoral immune responses. They are overexpressed in numerous tumor types and have thus become crucial therapeutic targets. Monoclonal antibodies directed against these molecules have been recently developed and show promising but still mitigated clinical results. More importantly, their toxicity is still very high.
THERAVECTYS is developing novel innovative strategies based on its proprietary lentiviral technology. It has been shown that soluble forms of PD-1 and PD-L1 corresponding to their extracellular domains, are able to bind to their corresponding partner, therefore blocking the access to the natural ligand. These soluble forms have shown anti-tumor efficacy in different in vitro and in vivo models. Moreover, a soluble form of CD80 is able to bind to CTLA-4, thus moving the equilibrium of binding of natural CD80 towards CD28 and increasing anti-tumor immunity. We have chosen to vectorize the extracellular domains of PD-1, PD-L1 and CD80 with a secretion signal in our lentiviral vectors. We have made the proof of concept that these soluble forms are secreted at high levels in culture supernatants (25-40 ng/ml) after in vitro transduction of HEK293 cells. In vivo secretion is currently being evaluated in C57Bl6 mice in terms of quantity and durability of the secretion. The anti-tumor efficacy of these soluble forms will then be tested in vivo in syngenic tumor models of melanoma and mammary gland carcinoma.
Theravectys is also developing nanobodies against PD-1, PD-L1 and CTLA-4. Nanobodies are antibody fragments made of a single monomeric variable domain derived from Llama heavy chain antibodies. They have numerous advantages compared to human monoclonal antibodies since they show high target specificity and affinity, low toxicity and they are easy to manufacture. Moreover they are very homolog to human antibodies, therefore avoiding any neutralization by human natural antibodies. Theravectys is currently selecting the nanobody clone with the best affinity for PD-1, PD-L1 and CTLA-4. The anti-tumor activity of these selected clones will then be evaluated in in vivo syngenic tumor models. The vectorization of these nanobodies into our lentiviral vectors will also be assayed.
These two strategies should overcome the problems of toxicities observed with monoclonal antibodies while showing optimal anti-tumor efficacy.
JP Morgan - Bio Showcase
San Francisco, January 2015
Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences.
Emerging oncogenic viruses
San Pietro, June 2014
OMS/International agency for research on cancer. The objectives of the meeting will be the discussion and critical evaluation of the epidemiology, immunology, and biology of cancer-associated viruses.